Panagora Asset Management’s PTC Therapeutics PTCT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $7.26M | Sell |
88,956
-262,414
| -75% | -$18.9M | 0.02% | 391 |
|
|
2026
Q1 | $23.9M | Sell |
351,370
-8,467
| -2% | -$600K | 0.09% | 208 |
|
|
2025
Q4 | $27.3M | Buy |
359,837
+11,471
| +3% | +$834K | 0.1% | 182 |
|
|
2025
Q3 | $21.4M | Buy |
348,366
+62,309
| +22% | +$3.25M | 0.09% | 195 |
|
|
2025
Q2 | $14M | Sell |
286,057
-25,720
| -8% | -$1.22M | 0.06% | 228 |
|
|
2025
Q1 | $15.9M | Sell |
311,777
-239
| -0.1% | -$11.9K | 0.08% | 208 |
|
|
2024
Q4 | $14.1M | Sell |
312,016
-3,025
| -1% | -$129K | 0.07% | 201 |
|
|
2024
Q3 | $11.7M | Sell |
315,041
-59
| -0% | -$1.98K | 0.06% | 226 |
|
|
2024
Q2 | $9.64M | Buy |
315,100
+26,398
| +9% | +$855K | 0.05% | 223 |
|
|
2024
Q1 | $8.4M | Sell |
288,702
-14,253
| -5% | -$399K | 0.04% | 257 |
|
|
2023
Q4 | $8.35M | Sell |
302,955
-1,430
| -0.5% | -$32.7K | 0.05% | 246 |
|
|
2023
Q3 | $6.82M | Sell |
304,385
-16,028
| -5% | -$596K | 0.04% | 254 |
|
|
2023
Q2 | $13M | Sell |
320,413
-19,013
| -6% | -$930K | 0.08% | 205 |
|
|
2023
Q1 | $16.4M | Buy |
339,426
+36,267
| +12% | +$1.66M | 0.1% | 186 |
|
|
2022
Q4 | $11.6M | Buy |
303,159
+24,478
| +9% | +$1.02M | 0.08% | 235 |
|
|
2022
Q3 | $14M | Buy |
278,681
+42,992
| +18% | +$2.11M | 0.1% | 199 |
|
|
2022
Q2 | $9.44M | Sell |
235,689
-352
| -0.1% | -$12.3K | 0.06% | 263 |
|
|
2022
Q1 | $8.81M | Buy |
236,041
+10,299
| +5% | +$397K | 0.05% | 305 |
|
|
2021
Q4 | $8.99M | Buy |
225,742
+90,069
| +66% | +$3.45M | 0.05% | 310 |
|
|
2021
Q3 | $5.05M | Sell |
135,673
-8,921
| -6% | -$366K | 0.03% | 421 |
|
|
2021
Q2 | $6.11M | Sell |
144,594
-15,738
| -10% | -$674K | 0.03% | 400 |
|
|
2021
Q1 | $7.59M | Sell |
160,332
-194,782
| -55% | -$11.6M | 0.04% | 369 |
|
|
2020
Q4 | $21.7M | Sell |
355,114
-174,155
| -33% | -$10.3M | 0.13% | 153 |
|
|
2020
Q3 | $24.7M | Buy |
529,269
+41,077
| +8% | +$2.02M | 0.16% | 144 |
|
|
2020
Q2 | $24.8M | Buy |
488,192
+11,829
| +2% | +$581K | 0.16% | 129 |
|
|
2020
Q1 | $21.3M | Sell |
476,363
-122,904
| -21% | -$6.19M | 0.15% | 145 |
|
|
2019
Q4 | $28.8M | Buy |
599,267
+31,987
| +6% | +$1.36M | 0.13% | 173 |
|
|
2019
Q3 | $19.2M | Buy |
567,280
+41,020
| +8% | +$1.79M | 0.09% | 213 |
|
|
2019
Q2 | $23.7M | Buy |
526,260
+407,959
| +345% | +$16.1M | 0.11% | 192 |
|
|
2019
Q1 | $4.45M | Buy |
118,301
+1,625
| +1% | +$54.6K | 0.02% | 543 |
|
|
2018
Q4 | $4M | Sell |
116,676
-32,805
| -22% | -$1.18M | 0.02% | 533 |
|
|
2018
Q3 | $7.03M | Buy |
149,481
+47,718
| +47% | +$1.97M | 0.03% | 441 |
|
|
2018
Q2 | $3.43M | Buy |
101,763
+51,443
| +102% | +$1.6M | 0.01% | 670 |
|
|
2018
Q1 | $1.36M | Buy |
+50,320
| New | +$1.27M | 0.01% | 1042 |
|
|
2016
Q4 | – | Sell |
-983
| Closed | -$14K | – | 2409 |
|
|
2016
Q3 | $14K | Hold |
983
| – | – | ﹤0.01% | 2313 |
|
|
2016
Q2 | $7K | Hold |
983
| – | – | ﹤0.01% | 2242 |
|
|
2016
Q1 | $6K | Hold |
983
| – | – | ﹤0.01% | 2238 |
|
|
2015
Q4 | $32K | Buy |
983
+458
| +87% | +$13.5K | ﹤0.01% | 2084 |
|
|
2015
Q3 | $14K | Buy |
+525
| New | +$22.5K | ﹤0.01% | 2189 |
|
|
2014
Q4 | – | Sell |
-1,283
| Closed | -$56K | – | 2331 |
|
|
2014
Q3 | $56K | Hold |
1,283
| – | – | ﹤0.01% | 1995 |
|
|
2014
Q2 | $34K | Sell |
1,283
-60
| -4% | -$1.28K | ﹤0.01% | 2168 |
|
|
2014
Q1 | $35K | Buy |
+1,343
| New | +$36.1K | ﹤0.01% | 2151 |
|
|
2013
Q4 | – | Sell |
-13,383
| Closed | -$287K | – | 2241 |
|
|
2013
Q3 | $287K | Buy |
+13,383
| New | +$233K | ﹤0.01% | 1524 |
|
Other funds holding PTCT
RI
JT
Panagora Asset Management's PTCT Position: Q2 2026 in Review
Panagora Asset Management reduced its PTC Therapeutics (PTCT) stake by 75% in Q2 2026, selling an estimated $18.9M and leaving 88,956 shares worth $7.26M. The position accounts for 0.02% of the portfolio, ranked #391.
Panagora Asset Management first reported a position in PTCT in Q3 2013 and has held it in 43 quarters since. The position peaked at $28.8M in Q4 2019. 382 funds tracked by Wall St. Rank hold PTCT as of Q2 2026.
- Panagora Asset Management held 88,956 shares of PTC Therapeutics worth $7.26M as of Q2 2026.
- Panagora Asset Management sold 262,414 PTC Therapeutics shares in Q2 2026, an estimated $18.9M.
- PTC Therapeutics made up 0.02% of Panagora Asset Management's portfolio in Q2 2026, its #391 holding.
- Panagora Asset Management first reported a position in PTC Therapeutics in Q3 2013 and has held it in 43 quarters since.
- Panagora Asset Management's PTC Therapeutics position peaked at $28.8M in Q4 2019.
- 382 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2026.
Based on Panagora Asset Management's 13F filing for Q2 2026, filed 6 Aug 2026.